A total of 18 healthy volunteers will participate in this four-week, within-groups,
double-blind, placebo-controlled study. The study has two phases separated by a 4 to 15-day
washout period. Subjects will be randomly assigned to receive either 40 mg atomoxetine or
placebo. For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. After
receiving medication or placebo for three days, subjects will have a 6-hour laboratory
session, where responses to physical and psychological stress of a 20 mg/70 kg (20 mg
maximum) dose of d-amphetamine will be measured. Several physiological, hormonal, and
subjective outcome measures will be obtained during the experimental sessions. Subjects will
then have a 4-15 day washout period and will be crossed over to the alternative treatment for
Phase II.